Turning Disordered Proteins “Druggable” with Intrametics TM
Time: 9:00 am
day: Conference Day Two
Details:
- Elevating that intrinsically disordered proteins (IDPs) represent half of the human proteins and perform a plethora of biological functions
- Demonstrating how, IntrameticsTM , IDP Pharma’s proprietary technology, enables for the first-time the inhibition and cellular degradation of IDPs with peptidomimetics
- Successfully delivering four peptide-derived drug candidates targeting novel IDP targets, with one at clinical stage
